This article is intended for primary care clinicians, infectious disease specialists, emergency medicine specialists, nurses, pharmacists, and other clinicians who care for patients at risk for oropharyngeal gonorrhea.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This Enduring Material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 9/1/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 0.25 AAFP Prescribed credits.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
AAFP Accreditation Questions
Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number 0461-0000-17-013-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 1/26/2017
Valid for credit through: 1/26/2018, 11:59 PM EST
processing....
Mouthwash is rarely considered as a potential asset against disease, but certain rinses have been recognized for many years for improving oral health. According to a review by Ross and colleagues, which appeared in the spring 1989 issue of the Journal of Clinical Dentistry, [1] Listerine (Johnson & Johnson Consumer Inc) safely improves oral health. In 4 clinical trials lasting 6 months or longer, Listerine was effective in reducing both supragingival plaque and gingivitis. In addition, 2 microbiology studies found no development of resistant microorganisms or other presumptive oral pathogens among Listerine users.
The prevalence of gonorrhea has increased among men who have sex with men (MSM). The authors of the current study believe that rates of gonorrhea may increase further as the threat of HIV infection decreases with wider use of preexposure prophylaxis. Therefore, simple interventions that can prevent the spread of gonorrhea and antimicrobial resistance of gonorrhea are critically important. The current research by Chow and colleagues combines an in vitro study with a small clinical trial to evaluate whether Listerine may be effective against gonorrhea.
Listerine mouthwash inhibits the growth of oral gonorrhea bacteria in the mouth, a new study has found.
In a randomized trial, 52% (95% confidence interval [CI], 34%-69%), of the pharyngeal surfaces of men who rinsed and gargled with the mouthwash for 1 minute tested positive for Neisseria gonorrhoeae compared with 84% (95% CI, 64%-95%) of the pharyngeal surfaces of men who rinsed and gargled with a saline solution.
"With daily use it may increase gonococcal clearance and have important implications for prevention strategies," Eric P.F. Chow, PhD, from the Melbourne Sexual Health Centre in Melbourne, Australia, and colleagues write in an article published online December 20 in Sexually Transmitted Infections.[2]
Gonorrhea infections among men are increasing in many countries as condom use declines, mostly among MSM, the researchers explain.
In Australia, new diagnoses doubled from 6892 to 11,508 in the last 5 years, with 70% of these infections in MSM, the researchers write.
As the incidence of the infections rises, so do concerns about the risk for antibiotic resistance, highlighting the need for new preventive measures, they say.
As early as 1879, well before the advent of antibiotics, the maker of Listerine claimed it could be used to cure gonorrhea. Until now, however, no published research has tested this claim.
To fill that gap, Dr Chow and colleagues assessed whether the mouthwash could curb the growth of N gonorrhoeae in laboratory tests and in a clinical trial of MSM.
In the laboratory tests, the researchers applied various dilutions up to 1:32 of Listerine Cool Mint and Total Care to cultures of N gonorrhoeae to see which, if any, of them might curb growth of the bacteria. Both formulations contain 21.6% alcohol. The authors also applied a saline solution to an identical set of cultures.
Listerine at dilutions up to 1 in 4, applied for 1 minute, significantly reduced the number of N gonorrhoeae on the culture plates. The saline solution had no effect.
Encouraged, the researchers undertook a clinical trial, starting with 196 MSM who had tested positive for gonorrhea in their mouths or throats and were returning for treatment at Melbourne Sexual Health Centre between May 2015 and February 2016.
At this return visit, 58 of the men once again tested positive for the bacteria on their pharynxes. The median age of these men was 27 years. They had had a median of 6 sexual partners in the previous 3 months.
The researchers assigned 33 men to rinse and gargle for 1 minute with the mouthwash, and 25 to rinse and gargle with a saline solution for 1 minute.
The researchers then retested the men and found that those in the mouthwash group were 80% less likely to test positive for gonorrhea on their pharyngeal surface compared with the other men (odds ratio [OR], 0.20; 95% CI, 0.07-0.72).
In a similar manner, of the men who gargled and rinsed with the mouthwash, 57% (95% CI, 34%-77%) tested positive for gonorrhea at the tonsillar fossae compared with 90% (95% CI, 68%-99%) of those in the saline group (P =.016).
Men in the mouthwash group were 86% less likely to test positive on this surface than were men in the saline group (OR, 0.14; 95% CI, 0.03-0.77).
Of the men in the mouthwash group, 57% (95% CI, 34%-77%) had infection on the posterior oropharynx compared with 70% (95% CI, 46%-88%) of those in the saline group.
Although the difference between groups in pharyngeal surface infections was statistically significant (P =.013), as was the difference in tonsillar fossae infections (P =.016), the difference in posterior oropharynx infections was not (P =.277).
The researchers acknowledge that the follow-up time in the study was short, so it is possible that the effects of the mouthwash might be short lived. However, the laboratory test results suggest a longer-term effect, they reason.
Whether an oral mouthwash can reduce gonorrhea infections of the anus and urethra remains to be seen. Some studies have suggested that pharyngeal gonorrhea spreads to the anus and urethra, the researchers note.
As people are less likely to have symptoms from oral gonorrhea infections, they are less likely to receive treatment rapidly than with urethral infections, the researchers point out.
A larger trial is currently underway to confirm the results of this study and see whether the use of mouthwash could curb the spread of gonorrhea, according to a news release from the journal.
The Australian National Health and Medical Research Council funded the study. The researchers have disclosed no relevant financial relationships.
Sex Transm Infect. Published online December 20, 2016.